A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Inclusion Criteria:

1. Adult male or female participants 18 years or older with a confirmed diagnosis ofsymptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria.
2. Completed 6 to 12 months (± 2 weeks) of initial therapy, during which the participantwas treated to best response, defined as the best response maintained for 2 cyclesafter the M-protein nadir is reached.
3. Documented major response (PR, VGPR, CR) according to the International MyelomaWorking Group (IMWG) uniform response criteria, version 2011, after this initialtherapy.
4. Female participants who:

• Are postmenopausal for at least 1 year before the screening visit, OR
• Are surgically sterile, OR
• If they are of childbearing potential, agree to practice 2 effective methods ofcontraception, at the same time, from the time of signing the informed consentthrough 90 days after the last dose of study drug, OR
• Agree to practice true abstinence, when this is in line with the preferred andusual lifestyle of the participant. (Periodic abstinence [eg, calendar,ovulation, symptothermal, postovulation methods] and withdrawal are notacceptable methods of contraception.) Male participants, even if surgically sterilized (that is, status postvasectomy), who:
• Agree to practice effective barrier contraception during the entire studyTreatment period and through 90 days after the last dose of study drug, OR
• Agree to practice true abstinence, when this is in line with the preferred andusual lifestyle of the participant. (Periodic abstinence [example, calendar,ovulation, symptothermal, postovulation methods for the female partner] andwithdrawal are not acceptable methods of contraception.)

5. Voluntary written consent must be given before performance of any study-relatedprocedure not part of standard medical care, with the understanding that consent maybe withdrawn by the participant at any time without prejudice to future medical care.
6. Complete documentation of the details of the initial therapy before randomizationincluding cytogenetics and International Staging System (ISS) is available.
7. Eastern Cooperative Oncology Group Performance Status of 0 to 2.
8. Suitable venous access for the study-required blood sampling and consent for thespecific amounts that will be taken.
9. Is willing and able to adhere to the study visit schedule and other protocolrequirements including blood sampling and bone marrow aspiration.
10. Must meet the following clinical laboratory criteria at study entry:

• Absolute neutrophil count (ANC) greater than or equal to (≥) 1,000 per cubicmillimeter (/mm^3) without growth factor support and platelet count ≥75,000/mm^3.Platelet transfusions to help participants meet eligibility criteria are notallowed within 3 days before randomization.
• Total bilirubin less than or equal to (≤) 1.5*the upper limit of the normal range (ULN).
• Alanine aminotransferase and aspartate aminotransferase ≤ 3*ULN.
• Calculated creatinine clearance ≥ 30 milliliter per minute (mL/min) (using theCockcroft-Gault equation).

Exclusion Criteria:

1. Multiple myeloma that has relapsed after, or was not responsive to, initial therapy.
2. Prior SCT.
3. Radiotherapy within 14 days before randomization.
4. Diagnosed or treated for another malignancy within 5 years before randomization orprevious diagnosis with another malignancy. Participants with nonmelanoma skin canceror carcinoma in situ of any type are not excluded if they have undergone completeresection.
5. Female participants who are lactating and breastfeeding or have a positive serumpregnancy test during the Screening period.
6. Major surgery within 14 days before randomization.
7. Central nervous system involvement.
8. Infection requiring intravenous (IV) antibiotic therapy or other serious infectionwithin 14 days before randomization.
9. Diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly,endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS), plasma cellleukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferativesyndrome.
10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolledhypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure,unstable angina, or myocardial infarction within the past 6 months.
11. Systemic treatment with strong cytochrome P450 3A (CYP3A) inducers (rifampin,rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or St. John's wortwithin 14 days before randomization.
12. Ongoing or active infection, known human immunodeficiency virus (HIV) positive, activehepatitis B or C infection.
13. Comorbid systemic illnesses or other severe concurrent disease that, in the judgmentof the investigator, would make the participant inappropriate for entry into thisstudy or interfere significantly with the proper assessment of safety and toxicity ofthe prescribed regimens (example, PN that is Grade 1 with pain or Grade 2 or higher ofany cause).
14. Psychiatric illness or social situation that would limit compliance with studyrequirements.
15. Known allergy to any of the study medications, their analogues, or excipients in thevarious formulations of any agent.
16. Inability to swallow oral medication, inability or unwillingness to comply with thedrug administration requirements, or gastrointestinal (GI) procedure that couldinterfere with the oral absorption or tolerance of treatment.
17. Treatment with any investigational products within 30 days before randomization.